Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.58 |
| ▸ | VNN1 | O95497 | 5/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.42 |
| ▸ | ACACB | O00763 | 2/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954826 | 0.84 | VNN1 (0.58) | HDAC1HDAC6HDAC3HDAC2VNN1 | |
| SCHEMBL21381213 | 0.81 | HDAC3 (0.61) | HDAC1HDAC6HDAC3HDAC2VNN1 | |
| SCHEMBL21381218 | 0.81 | VNN1 (0.54) | VNN1KCNH3 | |
| SCHEMBL20185852 | 0.80 | VNN1 (0.53) | HDAC1HDAC6HDAC3HDAC2VNN1 | |
| SCHEMBL22191474 | 0.79 | HDAC1 (0.58) | HDAC1HDAC6HDAC3HDAC2VNN1 | |
| SCHEMBL18249767 | 0.78 | HDAC1 (0.57) | HDAC1HDAC6HDAC3HDAC2VNN1 | |
| SCHEMBL12674818 | 0.77 | VNN1 (0.63) | HDAC6VNN1ACACB | |
| SCHEMBL23094442 | 0.76 | HDAC1 (0.59) | HDAC1HDAC6HDAC3HDAC2VNN1 | |
| SCHEMBL4066965 | 0.76 | MEN1 (0.50) | HDAC1HDAC6SMN1; SMN2 | |
| SCHEMBL18306898 | 0.75 | F2 (0.49) | HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292157-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292157-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | VNN1, VAT1, CMA1 | HDAC1 395/4885HDAC6 767/4885HDAC3 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.